Last reviewed · How we verify
No OAC (no-oac)
5-7 sentence executive brief for pharma professionals — Eliquis (apixaban), Pfizer Inc., mechanism of action not specified, key indications include Acute Ischemic Stroke, Atrial Fibrillation or Flutter with a High Risk of Stroke, Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke, Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF, Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF, clinical differentiation not specified, commercial significance is high with $63.6B revenue, pipeline developments not specified
At a glance
| Generic name | no-oac |
|---|---|
| Sponsor | Pfizer |
| Drug class | Direct Oral Anticoagulant |
| Target | Factor Xa |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Acute Ischemic Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
- Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF
Common side effects
Drug interactions
- Aspirin
- Clopidogrel
- Dabigatran
- Edoxaban
- Apixaban
- Rivaroxaban
- Warfarin
- Pentasaccharides
- Antiplatelets
- Anticoagulants
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Key clinical trials
- Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation (NA)
- PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years
- A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
- Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control
- Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure (PHASE4)
- Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy (PHASE3)
- Avoiding Anticoagulation After IntraCerebral Haemorrhage (PHASE3)
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No OAC CI brief — competitive landscape report
- No OAC updates RSS · CI watch RSS
- Pfizer portfolio CI